openPR Logo
Press release

SMi Reports: Celltrion Healthcare Present Proven Case Study Insight at 8th Annual Biosimilars Industry Summit

06-27-2017 12:46 PM CET | Health & Medicine

Press release from: SMi Group

Biosimilars & Biobetters

Biosimilars & Biobetters

SMi Group are delighted to welcome the expertise of Celltrion Healthcare when they present a keynote address at the 8th annual industry summit on Biosimilars & Biobetters this September.

Highlights from the talk presented by HoUng Kim, Division Head for Strategy and Operations include:

The Challenges of Gaining Approval: Attendees will leverage stringent standard criteria to overcome challenges in regulation as Celltrion draw from experience on the successful approval of two biosimilar drugs.

Publishing Data: The presentation will cover ARD requirement on sensitivity analysis and discuss ways in which Celltrion demonstrated a similar response rate regardless of different statistical approaches.

Future Landscape of Biosimialrs: The talk will look ahead into the tremendous expansion expected in biosimilars surrounding the patent expiry of top selling biologics in coming years. Progressive outlook will also be given on the industry shift towards personalised and convenient treatments.

Other speakers on the panel for 2017 will include Boehringer Ingelheim; Norwegian Medicines Agency; QuintilesIMS; Gedeon Richter; Teva Pharmaceuticals; Biocon; Prolong Pharmaceuticals; Merck Group and Lupin Europe.

Further details are available online at www.biosimilars-europe.com

Biosimilars & Biobetters
27th & 28th September 2017
Holiday Inn Kensington Forum, London UK

--end –

Contact Information:
For media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

For all other inquiries contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

2 Floor Harling House
47-51 Great Suffolk Street

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SMi Reports: Celltrion Healthcare Present Proven Case Study Insight at 8th Annual Biosimilars Industry Summit here

News-ID: 596641 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Biosimilars

Global Biosimilars Market 2021-2028 | Price Advantage of Biosimilars Over Biolog …
The global Biosimilars market focuses on encompassing major statistical evidence for the Biosimilars industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition, the Biosimilars study also shifts its attention with an in-depth
Growth of the Biosimilars Market Is Mainly Driven by Increasing Number of Approv …
A biosimilar is a biologic medical product that is similar to another already approved biological medicine, in terms of quality, safety, and efficacy. Biosimilars are a class of therapeutic drugs that provide additional treatment options and help reduce healthcare costs. Thus, there is an increasing demand for biosimilar drugs due to increasing prevalence of autoimmune diseases, key factor driving the growth of the biosimilars market. According to the National Stem
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Global Oral Biologics and Biosimilars Market | Global Oral Biologics and Biosimi …
The oral biologics and biosimilar market contain of sales of oral biologics and biosimilar products and associated services utilized to treat chronic syndromes such as diabetes, arthritis, cancer. Biologics are drugs completed from living cells using exceedingly complex technology while biosimilars are generated to function similarly to biologics but are not matching to biologics. Biosimilars offer energetic properties as any licensed biologic drug. The oral biologics and biosimilar market encompass
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million